GlassScriptPhysician profile
Andrew J Sakiewicz
NPI 1497708416
$2,823.09
in general payments reported to CMS, 2019-2025
24 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $64.81 · 2021: $87.68 · 2022: $350 · 2023: $446 · 2024: $638 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,823.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $551.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $352.64 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.80 | 2019-2025 | Jardiance |
| Pfizer INC. | $230.79 | 2019-2024 | |
| Novo Nordisk INC | $227.61 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $164.42 | 2019-2025 | Wainua, Farxiga, Bevespi Aerosphere |
| Janssen Pharmaceuticals, INC | $149.13 | 2019-2023 | Xarelto |
| Abbott Laboratories | $147.17 | 2020-2023 | Mitraclip |
| Scpharmaceuticals INC. | $134.63 | 2024-2025 | |
| Amgen INC. | $99.64 | 2019-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $92.18 | 2025 | Onpattro |
| Merck Sharp & Dohme LLC | $87.11 | 2022-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.25 | 2021-2024 | Lifevest |
| Daiichi Sankyo INC. | $42.55 | 2024-2025 | Injectafer |
| Boston Scientific Corporation | $31.40 | 2025 | Watchman Flx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $28.61 | 2019 | |
| Celonova Biosciences, INC. | $26.76 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $26.54 | 2025 | Exparel |
| Kiniksa Pharmaceuticals International, Plc | $22.43 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $19.43 | 2024 | Opsumit |
| Esperion Therapeutics, INC. | $18.48 | 2024 | Nexletol |
| Amarin Pharma, INC. | $17.43 | 2019 | |
| Glaxosmithkline, LLC. | $16.72 | 2025 | Arexvy, Shingrix |
| Lilly USA, LLC | $14.61 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Sakiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.